161 related articles for article (PubMed ID: 33001012)
21. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
22. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
23. Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis.
Sarafian TA; Tashkin DP; Roth MD
Toxicol Appl Pharmacol; 2001 Aug; 174(3):264-72. PubMed ID: 11485387
[TBL] [Abstract][Full Text] [Related]
24. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
26. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.
Fujiwara M; Egashira N
J Pharmacol Sci; 2004 Dec; 96(4):362-6. PubMed ID: 15599103
[TBL] [Abstract][Full Text] [Related]
27. [Dependence and Cytotoxicity of Components of Cannabis].
Funada M; Tomiyama KI
Yakugaku Zasshi; 2020; 140(2):205-214. PubMed ID: 32009044
[TBL] [Abstract][Full Text] [Related]
28. Dark Classics in Chemical Neuroscience: Δ
Banister SD; Arnold JC; Connor M; Glass M; McGregor IS
ACS Chem Neurosci; 2019 May; 10(5):2160-2175. PubMed ID: 30689342
[TBL] [Abstract][Full Text] [Related]
29. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
30. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
31. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
32. Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors.
Takeda S; Jiang R; Aramaki H; Imoto M; Toda A; Eyanagi R; Amamoto T; Yamamoto I; Watanabe K
J Pharm Sci; 2011 Mar; 100(3):1206-11. PubMed ID: 20891010
[TBL] [Abstract][Full Text] [Related]
33. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
34. Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.
Wiley JL; Lefever TW; Cortes RA; Marusich JA
Pharmacol Biochem Behav; 2014 Sep; 124():123-8. PubMed ID: 24887450
[TBL] [Abstract][Full Text] [Related]
35. Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.
Lombard C; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Nov; 339(2):607-17. PubMed ID: 21831965
[TBL] [Abstract][Full Text] [Related]
36. Adolescent Δ
Jouroukhin Y; Zhu X; Shevelkin AV; Hasegawa Y; Abazyan B; Saito A; Pevsner J; Kamiya A; Pletnikov MV
Biol Psychiatry; 2019 Jun; 85(11):891-903. PubMed ID: 30219209
[TBL] [Abstract][Full Text] [Related]
37. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
39. Effects of Δ(9)-tetrahydrocannabinol (THC) on human amniotic epithelial cell proliferation and migration.
Yao JL; He QZ; Liu M; Chang XW; Wu JT; Duan T; Wang K
Toxicology; 2018 Feb; 394():19-26. PubMed ID: 29191629
[TBL] [Abstract][Full Text] [Related]
40. Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.
Černe K
Arh Hig Rada Toksikol; 2020 Mar; 71(1):1-11. PubMed ID: 32597140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
